Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced.

Similar presentations


Presentation on theme: "Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced."— Presentation transcript:

1 Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced nephropathy was induced in rats, after which control and ADRIA nephropathy rats were treated with the PP... Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced nephropathy was induced in rats, after which control and ADRIA nephropathy rats were treated with the PPAR-γ agonist pioglitazone (12 mg/kg body wt) for 6 weeks. Thereafter, animals were euthanized, and glomerular TRPC6 (A) protein and (B) mRNA expression was determined. In addition, protein expression of (C) desmin and (D) nephrin was measured. Protein expression is depicted as percentage of vehicle-treated rats. In addition, (E) urinary albumin-to-creatinine ratio (micrograms per millimolar), (F) IgG-to-creatinine ratio (micrograms per millimolar), and (G) percentage of glomerular lesions were assessed; n=8 animals per group. Statistical significance was determined using ANOVA followed by Bonferroni post hoc test. Ctr, control. *P<0.05 versus vehicle-treated control rats; #P<0.05 versus ADRIA–treated control rats. Ramon Sonneveld et al. JASN 2017;28: ©2017 by American Society of Nephrology


Download ppt "Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced."

Similar presentations


Ads by Google